Device Medical Device

(8305) Azurion 7 B12

Payments companies reported to CMS as associated with (8305) Azurion 7 B12. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$2,647associated payments (2023-2025)

7clinicians with associated payments

1company reporting

By year

2023 $2,647

Payments reported as associated with (8305) Azurion 7 B12, per program year, as reported to CMS.

Who makes it

Philips Electronics North America Corporation $2,647 associated with (8305) Azurion 7 B12 (2023-2025)

Specialties most often involved

Pediatric Cardiology $1,823

Physician Assistant $807

Interventional Cardiology $17.39

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with (8305) Azurion 7 B12

These are the largest totals companies reported as associated with (8305) Azurion 7 B12. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Tammy Dichiara	Norfolk, VA	Physician Assistant	$806.94
Elliot Tucker	Norfolk, VA	Pediatric Cardiology	$770.99
John Reed	Norfolk, VA	Pediatric Cardiology	$464.82
Jeremy Asnes	New Haven, CT	Pediatric Cardiology	$408.36
Konstantin Averin	New Hyde Park, NY	Pediatric Cardiology	$134.51
Grant Burch	Portland, OR	Pediatric Cardiology	$44.48
Edward Tuohy	Fairfield, CT	Interventional Cardiology	$17.39

Prescribed (8305) Azurion 7 B12?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.